Ibogaine Questions to Ask a Clinic Before You Consent

Definition box

Definition: Ibogaine questions to ask a clinic are informed-consent prompts for anyone considering physician-supervised IV ibogaine infusion—psychoactive intravenous ibogaine with consult → cardiac screening → continuous monitoring → integration. Good questions force honesty about route (oral vs IV), QTc risk, emergency plans, evidence limits, and geography. Evidence gap: Most published clinical literature is oral; Cherian/MISTIC = oral ibogaine + IV magnesium support—not IV-ibogaine proof. This checklist is educational—not a clearance algorithm and not a promise you will qualify. Ibogaine is U.S. Schedule I / not FDA-approved. Provisional Mexico programs discussed on this site ≠ FDA/US clinics. No DIY dosing. No cure claims.

Quotable answer (52 words)

Before consenting to ibogaine treatment, ask whether the psychoactive dose is oral or intravenous, how QTc is monitored, what emergency transfer looks like, and whether MISTIC is correctly labeled oral plus IV magnesium. IV ibogaine infusion still carries cardiac risk. No cure guarantees. Not FDA-approved. Not medical advice.

How to use this consent toolkit

Print or save these questions. Ask for written answers. If staff mock you for asking, that is data.

Pair with: /blog/how-to-choose-an-ibogaine-clinic · /blog/cheap-ibogaine-clinic-red-flags · /safety-and-screening · /blog/what-to-expect-iv-ibogaine-session.

Block A — Identity, route, and product

1. Is the psychoactive dose oral ibogaine HCl, another oral product, or psychoactive IV ibogaine?
2. If IV fluids/magnesium/antiemetics are used, are they labeled as support only?
3. What is the exact substance identity and purity testing documentation?
4. Who compounds or sources the drug product, and who is the responsible physician?

Entity teaching: /what-is-ibogaine-infusion · /blog/ibogaine-oral-vs-iv · /blog/electrolytes-support-iv-vs-psychoactive-iv.

Block B — Cardiac and monitoring (non-negotiable)

5. What pre-infusion ECG and lab panel do you require? 6. What QTc threshold triggers delay or cancellation? 7. Is continuous cardiac monitoring used throughout the acute window? 8. Who reads the monitor in real time (credentials)? 9. Where is the nearest emergency defibrillation/transfer plan—on paper?

Anchors: Knuijver et al. (*Addiction*, 2021) oral QTc teaching; this does not make risk optional for IV discussions. /blog/ibogaine-ecg-checklist · /blog/ibogaine-side-effects · /blog/ibogaine-contraindications · /blog/ibogaine-drug-interactions-qtc.

Block C — Medications, CYP2D6, and polysubstance

10. Who reconciles my full medication/supplement list for QT and CYP interactions? 11. How do you handle benzodiazepines, methadone, SSRIs, or antibiotics if present? 12. Do you discuss CYP2D6 inhibitors/genotyping as risk literacy—without selling it as a cure?

Deep dives: /blog/ibogaine-cyp2d6-metabolism · /blog/ibogaine-and-benzodiazepines · /blog/ibogaine-vs-methadone · /blog/ibogaine-vs-suboxone.

Reminder: No DIY benzo tapers from clinic marketing emails.

Block D — Evidence honesty (catch the hype)

13. Do you claim an FDA approval or labeled cure rate? (Correct answer: no.) 14. When you cite Stanford/Nature Medicine/MISTIC, do you state oral ibogaine + IV magnesium, open-label, small N? 15. Do you invent psychoactive-IV RCT success percentages?

Anti-hype: /blog/ibogaine-cure-rate-claims · /blog/stanford-ibogaine-mistic. Mosca et al.: limited RCTs; cardiotoxicity concerns.

Block E — Outcomes, aftercare, and relapse realism

16. What aftercare is included versus upsold? 17. How do you talk about relapse without shame or fake lifetime guarantees? 18. Who do I call at 2 a.m. week two if cravings or insomnia spike?

/blog/ibogaine-aftercare-integration · /blog/ibogaine-program-duration · condition hubs without cures: /ibogaine-for-addiction · /ibogaine-for-depression · /ibogaine-for-ptsd.

Block F — Money, pressure, and geography

19. What exactly is included in the price (monitoring nights, physician coverage, labs, transfer)? 20. Are deposits refundable if cardiac screening fails? 21. Do you pressure same-day payment before ECG review? 22. Are you clear that provisional Mexico programs discussed in this ecosystem are not FDA-approved U.S. clinic care?

/blog/cost-of-ibogaine-treatment · /blog/does-insurance-cover-ibogaine · /blog/ibogaine-mexico-medical-vs-tourism · /blog/is-ibogaine-legal-us.

Block G — Consent capacity and coercion

23. Can I say no after arriving without humiliation or hidden fees designed as punishment? 24. Is a companion allowed, and are privacy practices explained? 25. Are risks of death/arrhythmia stated in plain language in the consent form?

Process: /how-it-works · Apply only after safety read: /apply.

Scoring heuristic (not a medical score)

| Pattern | Meaning | |---------|---------| | Clear route + telemetry + emergency plan + no cure claims | Continues conversation | | Oral-as-IV laundry / MISTIC misuse / “80% cured” | Walk | | Deposit before ECG language | Walk | | “Stop all benzos in 48 hours” without physician ownership | Walk | | Mocking cardiac questions | Walk |

Sample email you can send (copy/paste)

> I am evaluating physician-supervised care only. Please answer in writing: (1) Is the psychoactive dose oral or IV ibogaine? (2) What ECG/lab criteria and continuous monitoring do you use? (3) What is your emergency transfer plan? (4) When you cite MISTIC/Nature Medicine, do you label it oral ibogaine + IV magnesium? (5) Do you make cure/guarantee claims? (6) Are deposits refundable if screening fails? I understand ibogaine is not FDA-approved and that programs abroad are not U.S. FDA clinics.

If the reply is vague marketing, you already have your answer.

Special questions for combo packages (5-MeO, ayahuasca, ketamine add-ons)

26. Are separate consents and separate risk discussions provided for each substance? 27. Who is medically responsible if adverse events occur after a stack? 28. Is any “toad/5-MeO add-on” optional—and can I decline without losing medical monitoring for ibogaine?

Comparisons: /blog/ibogaine-vs-5-meo-dmt · /blog/ibogaine-vs-ayahuasca · /blog/ibogaine-vs-ketamine-for-addiction.

Stimulant or alcohol-interest applicants should also disclose polysubstance context early: /blog/ibogaine-for-cocaine-stimulants · /blog/ibogaine-for-alcohol-use-disorder · fentanyl literacy /blog/ibogaine-for-fentanyl.

Microdosing sellers are not “clinics”—see /blog/ibogaine-microdosing-myths.

Soft CTA

Use questions first, hype never. Read /safety-and-screening, then request a confidential screening consult via /apply. FAQ: /faq.

FAQ

What is the single most important question? Whether the psychoactive dose is oral or intravenous—and whether continuous cardiac monitoring is real.

Should a clinic promise I will be cured? No. Treat cure guarantees as a red flag.

Is MISTIC proof of IV ibogaine? No. Oral ibogaine + IV magnesium, open-label.

Do these questions replace medical screening? No. They prepare you to participate in screening with clinicians.

Is ibogaine FDA-approved? No. Schedule I federally; not FDA-approved.

Are Mexico programs the same as U.S. FDA clinics? No. Provisional Mexico availability discussed here ≠ FDA/US clinics. Not legal advice.

What if staff refuse written answers? That refusal is itself an answer—slow down or leave.

Where should I go next? /safety-and-screening then /apply.

Medical disclaimer

Educational consent literacy only—not medical advice, legal advice, or a personal clearance checklist. Do not self-administer ibogaine. Cardiac events can be life-threatening. Seek licensed clinicians.

Sources (selected)

1. Cherian K.N. et al. *Nature Medicine*. 2024 — oral ibogaine + IV magnesium (MISTIC); open-label.
2. Knuijver T. et al. *Addiction*. 2021 — oral ibogaine HCl; QTc findings.
3. Mosca A. et al. *Current Neuropharmacology* — limited RCTs; cardiotoxicity concerns.
4. Glue P. et al. *J Clin Pharmacol* — CYP2D6 influences oral ibogaine PK (interaction literacy).
5. 21 CFR 1308.11 — Schedule I (ibogaine).